Patent SG-11201906744V-A (SG)
Title: Core/shell structure platform for immunotherapy
Inventor: SHEN HAIFA
IPC: A61P35/00
Filed: 2018-01-26
Abstract: WO 18/ 1408 26 A9 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 1111111111110110101011111011010 I 010 11011EMOHEMEM110111 (10) International Publication Number WO 2018/140826 A9 02 August 2018 (02.08.2018) W 1 PO I PCT (51) International Patent Classification: A61K 39/39 (2006.01) A61K 9/51 (2006.01) A61K 9/127 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/015601 (22) International Filing Date: 26 January 2018 (26.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/451,575 27 January 2017 (27.01.2017) US (71) Applicant: THE METHODIST HOSPITAL [US/US]; 6565 Fannin, MS D-200, Houston, Texas 77030 (US). (72) Inventor: SHEN, Haifa; 4313 Cynthia Street, Bellaire, Texas 77401 (US). (74) Agent: MOORE, Mark D.; Haynes and Boone, LLP, 2323 Victory Avenue, Suite 700, Dallas, Texas 75219 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) (54) Title: CORE/SHELL STRUCTURE PLATFORM FOR IMMUNOTHERAPY (57) : Disclosed are biocompatible core/shell compositions suitable for the Exemplary Vaccine Structure delivery of populations of mRNA molecules to mammalian cells. The disclosed core-shell structured multicomponent compositions are optimized for the delivery of mRNAs encoding one or more cancer- or tumor-specific antigens to a popu- lation of antigen presenting cells, including, for example, human dendritic cells, macrophages and B cells. Also disclosed are methods for use of these compositions as therapeutic cancer vaccines. Components: mRNA molecule : polymer or protein that binds mRNA and Ions a core structure topethec : mRNA core = lipid shell : PEG-2000 on Surface Of lipid shell : Affinity moiety attached to PEG-2000 : Small molecule or protein inside the ipid shell FIG. 2D [Continued on next page] WO 2018/140826 A9 lilil0H310101011MOHOIOMOIDHOIREIOMIDEORIO# Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (48) Date of publication of this corrected version: 11 October 2018 (11.10.2018) (15) Information about Correction: see Notice of 11 October 2018 (11.10.2018)